title: FDA approves radiopharmaceutical for metastatic prostate cancer.
abstract: The U.S. Food and Drug Administration approved radium-223 dichloride for treatment of men with metastatic castration-resistant prostate cancer that has spread to the bone.
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; C581106:radium Ra 223 dichloride; D011883:Radium